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The E7 transforming protein of Human Papillomavirus type 16 (HPV16) is expressed in the skin of a line of FVB mice
transgenic for the E6 and E7 open reading frames of HPV16 driven from the aA crystallin promoter (FVBaAcryHPV16E6E7).
We have transferred skin from FVBaAcryHPV16E6E7 mice to naive or E7-primed syngeneic FVB recipients to assess
whether the E7 protein of HPV16 can function as a minor transplantation antigen (MTA) and promote skin graft rejection.
FVB mice did not reject E7 expressing tail or flank skin grafts. E7 immunized FVB 1 C57BL/6J mice recipients of FVBa-
AcryHPV16E6E7 1 C57BL/6J skin generated humoral and DTH responses to E7 in vivo and E7-specific CTL precursors in
the spleen, but failed to reject E7 expressing tail skin grafts by 100 days posttransfer. Thus although HPV16 E7 / ve
mesenchymal and endodermal tumors can be eliminated by an E7-specific immune response, the same protein is unable
to act as a MTA and promote graft rejection when expressed in skin cells. Lack of rejection of grafts expressing MTAs such
as E7 may be relevant to the immunology of epithelial tumors expressing tumor-specific antigens and to our understanding of
the immunology of diseases of the skin. q 1997 Academic Press
INTRODUCTION E6 and E7 genes of HPV16 driven off of the aA Crystallin
promoter (Frazer et al., 1995), which express E7 ectopi-
Infection of cervical epithelial cells by HPV16 initiates cally in the skin and develop skin disease and skin tu-
changes which can lead to malignant transformation of mors. DTH to HPV16E7 can be induced in mice grafted
these cells, and HPV16-associated cervical carcinomas with sufficient E7 expressing keratinocytes (KCs)
express two viral genes, E6 and E7, which encode pro- (McLean et al., 1993). However, patients and animals fail
teins responsible for maintaining the transformed pheno- to reject epithelial tumors that express HPV16E7 despite
type (Zur Hausen, 1991). Expression of the E6 and E7 the induced immune response. To investigate whether
genes of HPV16 in mice as transgenes also promotes E7 can act as a MTA and whether induced immune re-
tumor development (Kondoh et al., 1991; Griep et al., sponses to E7 protein can mediate rejection of E7 ex-
1993; Auewarakul et al., 1994; Sasagawa et al., 1994). pressing skin, we examined the fate of tail and flank
Immunization of mice with E7 protein has led to the iden- skin grafts from E7 transgenic donors to naive and E7-
tification of E7 B, Th, and T cytotoxic (Tc) epitopes (Tindle immunized recipient mice.
et al., 1990; Comerford et al., 1991; Tindle et al., 1991;
Feltkamp et al., 1993), and the Th epitope has been MATERIALS AND METHODS
shown to provide cognate help for antibody production Mice
in a wide range of MHC backgrounds (Tindle et al., 1991).
FVB mice (H-2q), homozygous aAcryHPV16E6/E7-lineSuch immune responses can protect mice specifically
19 transgenic FVB mice (#19) (Lambert et al., 1993),against challenge with tumorigenic cell lines expressing
C57BL/6J mice (H-2b), F1 (#19 1 C57BL/6J) hybrid miceE7 protein (Chen et al., 1992; Feltkamp et al., 1993; Tindle
(H-2q 1 H-2b), and F1 (FVB 1 C57BL/6J) hybrid miceet al., 1995).
(H-2q 1 H-2b) were obtained from the Animal ResourcesAntibody to HPV16E7 protein is observed in some pa-
Centre (Perth, Australia). Mice were 6–24 weeks of agetients with HPV16-associated cervical cancer (Jochmus-
and maintained under specific pathogen-free conditionsKudielka et al., 1989) and in FVB mice transgenic for the
in the Princess Alexandra Hospital animal house facility.
Protocols were approved by the institutional animal eth-
1 Current address: Department of Virology, Umea˚ University, S-90730 ics committee.
Umea˚, Sweden.
2 Current address: Sir Albert Sakzewski Virus Research Centre, Royal Induction of skin disease
Children’s Hospital, Brisbane, Australia, 4029.
Number 19 mice develop an inflammatory and hyper-3 To whom correspondence and reprint requests should be ad-
dressed. Fax: /61 7 3240 2048. E-mail ifrazer@gpo.pa.uq.edu.au. proliferative skin disorder particularly in areas of trauma
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FIG. 1. (A) Macroscopic appearance of induced skin disease and papilloma on a 14-week-old female #19 mouse. (B) Spontaneously occurring
diseased skin from a #19 mouse showing thickened epidermis and dermis, and a cellular infiltrate (H&E, 1100). This section shows the transition
from relatively normal skin (left) to thickened and hyperkeratotic skin of a lesion (right).
(Lambert et al., 1993). Skin disease similar to that oc- tated, and purified using a Bio-Rad 491 protein prepara-
tion cell, then dialyzed against a Tris-sodium chloridecurring spontaneously in older #19 mice was induced in
young (3 months) #19 mice by placing a glass tube of buffer and acetone precipitated before Western blot anal-
ysis to determine protein size.approximately 4 cm length with fire polished ends over
the tail and securing it in place with a wound clip for 1 –
Assay of E7 protein2 weeks. This procedure instigates irritation at the tail
base, which progresses to skin disease in 40% of the
Tissues for protein analysis were snap frozen in liquid
treated mice. Skin disease was induced within 2– 4
nitrogen and held at 0707. For further processing the
weeks in 4 of 10 #19 mice after placement of a glass
tissues were pulverized in a chilled mortar and pestle
tube over the tail. The skin abnormalities produced were
and assayed for HPV16E7 protein, using an ELISA cap-
comparable to those observed in older #19 mice which
ture assay standardized on HPV16E7 fusion protein, as
spontaneously developed skin disease. Skin was de-
previously described (Selvey et al., 1992). Serial dilu-
nuded of hair and developed significant scarring, with
tions of purified, thrombin-cleaved recombinant GST –
formation of papillomas (Fig. 1A). On histological exami-
HPV16E7 fusion protein of known concentration were
nation, both spontaneously occurring and induced skin
included in the assay to provide a standard curve and
disease demonstrated a thickening of the epidermis and
to determine the limit of detection of E7 protein.
dermis at the periphery of lesions (Fig. 1B), and centrally
epidermal loss, dermal fibrosis, and a predominantly mo- Reverse transcriptase PCR (RT-PCR) for mRNA
nonuclear cellular infiltrate in the dermis. analysis
Histology Mouse skin samples were collected directly into liquid
nitrogen and stored at 0707. The tissue was pulverized
Samples for histological analysis were collected into
using liquid nitrogen and a mortar and pestle, followed
10% neutral-buffered formalin, processed conventionally,
by homogenization using a Polytron Homogenizer (IKA-
and stained with haematoxylin and eosin (H&E).
Ultra-Turrax T25, Janke & Kunkel, Staufen, Germany) or
by homogenization alone. Total RNA was isolated usingProteins and peptides
the Micro-Scale Total RNA Separator kit (Clontech) or
the Qiagen RNeasy total RNA kit (Qiagen GmbH) andThe sequence and synthesis of a series of overlapping
peptides (GF101–GF109) spanning the E7 protein of resuspended in 10 ml (per 10 mg of starting sample) of
0.1% Diethyl pyrocarbonate-treated water and nucleicHPV16, peptide BT12D, which contains three B epitopes
and the universal T-helper epitope (DRAHYNI) of HPV16, acid concentration determined by spectrophotometer
analysis. For DNase treatment 1 mg of sample nucleicand a control peptide (GF110), which contains an HIV-1
gp120 B epitope and a Th epitope from HPV16E7, have acid was incubated in a 20- to 40-ml volume of 0.04 M
Tris–HCl, pH 7.5 (Sigma), 2 mM CaCl2 (ICN), 5 mM MgCl2previously been described (Tindle et al., 1991; Frazer et
al., 1995). A GST–HPV16E7 fusion protein was prepared (BDH), and 10 U/mg nucleic acid of DNase I (Promega)
for 30 min at 377, followed by a 5-min incubation at 607in Escherichia coli and purified as previously described
(Selvey et al., 1992). HPV16E7 was cleaved from the GST to inactivate the DNase. Samples were then stored at 47
prior to reverse transcriptase treatment. Each RNA sam-fusion protein with thrombin (Sigma), acetone precipi-
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ple (0.5 mg) was mixed in a total volume of 20 ml of a panniculus carnosus and principal vessels of the graft
bed. An appropriately sized donor graft was then alignedreaction mixture containing first strand buffer and 10 mM
DTT (Gibco BRL, Life Technologies), 20 units of rRNasin on the graft bed with hair growth opposite to the recipi-
ent. The graft was held in place with antibiotic-permeated(Promega), 0.5 mM dNTPs (Pharmacia), 2.5 mM random
hexamer (Perkin–Elmer–Cetus), and 120 units of Molo- Vaseline gauze (Bactigras) and covered with micropore
tape and elastic bandage (Coflex) until 7 days postgraft.ney murine leukemia virus reverse transcriptase (Gib-
coBRL, Life Technologies). RNA and random hexamer Bandages were then removed and graft takes estab-
lished. Grafts that were completely adherent at 8 or morewas first incubated at 707 for 10 min. The other solutions
were added and the reaction was allowed to proceed days posttransfer were judged technically successful.
for 30 min at 377 followed by inactivation of the reverse
Immunization protocoltranscriptase at 957 for 5 min. The HPV16E6–E7 se-
quence (nt 83 to 742) was amplified with 5* primer (ATG- Mice were immunized s.c. at the tail base with a prepa-
CACCAAAAGAGAACTGCAAT) and 3* primer (ACTTGC- ration of GST–HPV16E7 fusion protein (10 mg/mouse)
AACAAAAGGTTA). The mouse dihydrofolate reductase and Quil A (20 mg/mouse) in 50–100 ml of sterile PBS.
sequence was amplified as a control for integrity of the Control immunizations were with 20 mg of Quil A per
isolated mRNA (Stratagene). Ten microliters each of the mouse in 50–100 ml of PBS.
cDNA from the RT reaction was amplified by adding 40
ml of solution containing 3 pmol of each PCR primer, 1-Chloro-2,4-Di-Nitrobenzene (DNCB) treatment
amplification buffer, and 2 units of AmpliTaq DNA poly-
Mice were sensitized on the ear on the day of graftingmerase (Perkin–Elmer– Cetus). The reaction was sub-
with 10 mg or 0.5 mg of DNCB (Sigma) in 50 ml of vehiclejected to an initial DNA denaturation step at 947 for 3
(4:1 acetone:olive oil), and challenged on the flank at themin followed by 35 amplification cycles (947 for 15 sec,
graft site with 2 mg or 0.2 mg or 50 mg of DNCB in 50557 for 15 sec, 727 for 30 sec). The final elongation step
ml of vehicle or vehicle alone at 8 days postgraft. Forwas prolonged to 5 min. One-fifth of the amplification
sensitization and challenge of control mice, vehicle aloneproduct was separated by electrophoresis through a 2%
was applied.agarose gel, followed by Southern blot hybridization us-
ing the Amersham LIFE SCIENCE alkali blotting method
Antibody to HPV16E7 proteinand Hybond-N/ membrane. The blots were hybridized
with [a-32P]dCTP-labeled (Pharmacia Ready-to-Go DNA Antibody to HPV16E7 protein and peptides was mea-
labeling kit) HPV16 PCR product as a probe (amplified sured by ELISA as previously described (Tindle et al.,
using the primers described above from a pHPV16 plas- 1990). Antibody to E7 protein was measured by immuno-
mid) and detected by phosphorimage analysis (Molecu- precipitation, using E7 recombinant baculovirus-infected
lar Dynamics). SF9 cells (Selvey et al., 1992). Sera were mixed with cell
lysates prepared in RIPA buffer, and immune complexes
were isolated as described (Selvey et al., 1994). ImmuneSkin grafting
complexes were subjected to SDS–PAGE and immu-
Tail skin grafting followed the method of Bailey and noblot, and precipitated E7 was detected with a mono-
Usama (1960). Sections of donor skin were sliced from clonal antibody (6D) that is specific for the E7 protein of
the tail of euthanized mice, against the direction of hair HPV16 (Tindle et al., 1990).
growth, and directly transferred to an identically prepared
raw area on the recipient’s tail. Positioning of the graft DTH to E7 protein
placed the direction of hair growth opposite to that of
DTH to E7 protein was measured by ear challenge, asthe recipient so that graft takes could be distinguished.
previously described (Frazer et al., 1995), in E7/Quil AA length of fire-polished glass tubing was placed over
and Quil A immunized tail skin graft recipients, using 7–the tail to cover the grafts and was held in place with a
9 mg of GST–HPV16E7 fusion protein. Control ears ofwound clip for 4 days (to allow graft vascularization with-
the mice were unchallenged. DTH was measured in Quilout interference from the mice). A similar procedure was
A-immunized mice to control for any inflammatory effectfollowed for the transfer of flank skin to recipient tails.
of the E7 challenge antigen. Ear swelling was reportedGrafts that were completely adherent at 6 or more days
as the difference in thickness between the challengedfollowing transfer were judged technically successful.
and the control ear, 48 hr after challenge.Flank skin grafting followed the method of Mayumi et al.
(1988). Sections of donor skin were harvested at the level
CTL assay
of areolar connective tissue, then connective tissue, fat,
and the panniculus carnosus layer were removed and CTL precursor activity was assayed in splenocyte pop-
ulations following in vitro restimulation essentially as pre-10 1 10-mm grafts prepared. Graft sites were marked on
the thoracic wall of recipients, the epidermis and dermis viously described (Tindle et al., 1995). Splenic effector
cells were harvested and set up in culture with irradiatedincized and the freed skin removed while retaining the
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TABLE 1
Graft Outcome for HPV16 E7 Expressing and Non-E7 Expressing Skin Grafts
Graft outcomea
Donor skin and
Donor strain recipient graft site Recipient strain Days 7–10 Day 20 Days 80–100
#19 Tail C57BL/6J 4/10 0/8 0/8
FVB 10/10 10/10 3/3
#19 10/10 10/10 3/3
(#19 1 C57BL/6J) Flank (FVB 1 C57BL/6J) 5/5 5/5 NDb
(FVB 1 C57BL/6J) 4/4 4/4 NDb
a No. of recipients with surviving grafts/No. of recipients.
b Not determined.
EL-4 cells stably transduced with E7 (C2 cells) (Tindle et generally appeared thicker than comparable grafts to
#19 recipients, and histological examination of tail skinal., 1995) at an E:T ratio of 20:1. After 4 days in culture,
recombinant IL-2 (Gibco-BRL) 25 U/ml was added to the grafts at 49 days posttransfer revealed persistent thick-
ening of the epidermis and dermis, with a predominantlymedia and 4 days later the effectors were harvested,
washed, and set up in microtiter well culture with 1 1 mononuclear cellular infiltrate (Fig. 2). This cellular infil-
trate was considerably less than that seen in rejecting104 per well 51Cr-labeled C2 or EL4 target cells at an E:T
ratio of 50:1 and 10:1. Supernatants were harvested 4.5 hr #19 allografts on C57BL/6J recipients. At 100 days post-
transfer, #19 tail skin grafts showed persisting thickeninglater and 51Cr release quantified by g-counting. Specific
cytotoxicity was expressed as: of the epidermis and dermis, with minimal cellular infil-
trate, whether on #19 or on FVB recipients. These experi-[Experimental51Cr release]0 [Spontaneous51Cr release]
[Total51Cr release]0 [Spontaneous51Cr release] ments were extended to include the transfer of flank skingrafts from F1 (#19 1 C57BL/6J) and F1 (FVB 1 C57BL/
1 100 6J) donors to F1 (FVB 1 C57BL/6J) recipients, as the
H-2q background might be a determinant of nonrejection,
Tumor challenge experiments and again no graft rejection was observed (Table 1).
C57BL/6J mice were immunized s.c. at the tail base
with a preparation of GST–HPV16E7 fusion protein (50 Fate of grafts expressing higher levels of E7
mg/mouse) and the adjuvant Quil A (10 mg/mouse) (Spiko-
To determine whether level of E7 expression (see nextside, Iscotec Sweden) or with ovalbumin (Sigma: chicken
section) in grafted skin was a determinant of graft out-egg albumin) (50 mg/mouse) and Quil A (10 mg/mouse),
come, full thickness grafts of diseased skin from #19in 100 ml of sterile saline (0.9% sodium chloride) on Days
mice, in which E7 protein is detectable, were placed0 and 21. On Day 35, mice were challenged subcutane-
on the tail of FVB recipients. Grafts of diseased skin toously with 3 1 106 cells of the C2 line, an EL4-derived
syngeneic recipients were not rejected up to 100 dayscell line expressing HPV16E7 (Tindle et al., 1995), or with
after grafting. Histological examination of grafts of dis-the parental line, prepared in 100 ml of RPMI 1640 (Gibco
eased #19 skin 15–20 days after grafting showed a thick-BRL), and checked for palpable tumors every second day
ening of the epidermis and dermis with a mononuclearand up to 80 days posttumor challenge. Most tumors
cellular infiltrate within the dermis beneath the graft siteappeared between Days 10 and 15 posttumor challenge.
and often in surrounding muscle bundles (Fig. 2C). Grafts
from #19 recipients of #19-diseased skin were histologi-RESULTS
cally similar with a thicker cornified layer (Fig. 2D) andHPV16E7 transgenic skin grafts
generally a somewhat lesser cellular infiltrate.
To determine whether the E7 protein of HPV16 func-
tions as a MTA when expressed in epithelium, grafts of E7 expression in skin grafts
tail skin were transferred from HPV16E7 transgenic #19
mice to syngeneic FVB (H-2q) or allogeneic C57BL/6J To confirm that skin from #19 mice and F1 (#19 1
C57BL/6J) hybrid mice expressed E7, and that surviving(H-2b) recipients. All grafts were well vascularized by 9
days posttransfer. Allografts expressing H-2q with or skin grafts contained donor skin expressing HPV16E7,
skin samples were tested for expression of E6/E7 mRNAwithout HPV16E7 were, as expected, rejected by H-2b
mice by 10–14 days posttransplant. In contrast, grafts and E7 protein. Flank or tail skin, or grafted skin samples
originating from #19 mice (9/14) and F1 (#19 1 C57BL/from #19 mice (male or female) were not rejected by
female FVB or #19 recipients for up to 100 days post- 6J) hybrid mice (3/4) were positive for E6/E7 mRNA by
RT-PCR, while samples from FVB mice and F1 (FVB 1transfer (Table 1). Grafts of #19 tail skin to FVB recipients
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FIG. 2. Histological appearance of representative tail skin grafts at various times after grafting (all H&E, 1100). (A) #19 tail skin graft on #19
recipient, 7 weeks posttransfer: some thickening of the graft is seen. (B) #19 tail skin graft on FVB recipient, 7 weeks posttransfer. (C) #19 diseased
skin on FVB recipient at 18 days posttransfer showing gross epidermal and dermal thickening and a cellular infiltrate beneath the graft site. (D)
#19 diseased skin on #19 recipient at 18 days posttransfer, showing similar histology to C, but with a thicker cornified layer.
C57BL/6J) hybrid mice were all negative as expected. #19 mice, harvested from the flank of FVB recipients at
1 and 4 weeks posttransfer, tested positive by RT-PCRE6/E7-positive samples which weighed 10–50 mg pro-
duced an HPV16E6/E7 RT-PCR product of 660 bp, while for E6/E7 mRNA (Fig. 3). PCR amplified samples DNase
treated to remove contaminating DNA, and not subjectedlarger samples of 50 mg produced three RT-PCR prod-
ucts of 660, 478, and 360 bp (data not shown), spanning to reverse transcription, lacked the 660-bp band seen in
samples subjected to reverse transcription, confirmingthe HPV16E6E7 open reading frames and comparable to
product previously detected in #19 mouse tissue using that the positive signals could be attributed to E7 mRNA.
Diseased skin from #19 mice and nondiseased skindifferent primer sets (Griep et al., 1993). Tail skin grafts
weighing 10 mg produced insufficient quantities of to- from #19, FVB, F1 (#19 1 C57BL/6J) hybrid, and F1 (FVB
1 C57BL/6J) hybrid mice varying in age from 2 to 5.5tal RNA for E6/E7 mRNA analysis. Flank skin grafts from
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TABLE 2
Growth of HPV16 E7-Transduced Tumor
in E7-Immunized C57BL/6J Mice
Tumor challenge
Immunization EL4.E7 (C2) EL4
E7/Quil A 1/9a 8/8
OVA/Quil A 8/8 8/8
a No. of mice with tumor growth/No. of mice challenged.
mice immunized with HPV16E7/Quil A according to a
protocol shown to induce DTH to E7 and to prevent the
growth of tumor after challenge with an H-2b thymoma
expressing HPV16E7 termed C2 (Table 2). Graft outcome
was monitored for grafts judged technically successful,
which was defined as still present at Day 6 for tail skin
grafts and at Day 8 for flank skin grafts. #19 grafts were
retained by all HPV16E7 immunized FVB recipients (23/
23) to Days 7–10 posttransfer, and by all recipients (15/
15) observed to Days 80–100 (Table 3). The histologic
FIG. 3. Phosphorscreen image of a Southern blot of RT-PCR products, appearance of #19 grafts on E7-immunized recipients
from #19 mouse flank skin grafts, following hybridization with an HPV16
(FVB and #19 mice) was the same at 100 days posttrans-radiolabeled probe. Lanes 1– 4, E6/E7 PCR product amplified from
fer as that of grafts on unimmunized mice, with somecDNA and genomic DNA (Lanes 1, 3) and from genomic DNA alone
(Lanes 2, 4); templates were prepared from grafts harvested at 1 (Lane cellular infiltrate, consisting predominantly of large mo-
1, 2) and 4 (Lane 3, 4) weeks posttransfer. Lanes 5–8, as lanes 1–4 nonuclear cells deep in the dermis and around the mus-
but with addition of DNAse prior to PCR. Lanes 9, 10, DHFR amplifica- cle bundles. The histology of #19 and FVB flank skin was
tion; and lanes 11, 12, lack of E7-specific PCR product from F1 (FVB
also similar, whether grafted to the flank of E7/QuilA or1 C57BL/6J) hybrid control skin.
Quil A-immunized mice. In each case there was a slightly
thickened dermis at 77–96 days posttransfer, but other-
wise normal morphology compared to control skin sec-months, and equivalent in age to those used as donors
tions. Flank skin grafts of diseased skin from #19 tofor grafting experiments, was assayed for immunoreac-
E7/QuilA or Quil A-immunized FVB mice also showed ative E7 protein using an ELISA capture assay sensitive
to 0.05 ng E7/mg total cellular protein. Three of 10 sam-
ples of diseased skin tested from #19 mice, including 2 TABLE 3
samples from mice with induced skin disease, tested
Effect of HPV16 E7 Immunization on the Outcomepositive for E7 protein. Between 1.7 and 8.3 ng E7/mg
of E7 Expressing Skin Grafts
total cellular protein was detected. Nondiseased #19
skin expressed E7 protein at a level below assay sensitiv- Graft outcomeb
ity. These results are comparable to those obtained in
#19 Donor Recipient Graft Days Daysstudies of spontaneously occurring skin disease in #19
skin strain site Immunization a 7–10 80–100mice (Frazer et al., 1995).
To confirm that the HPV16E7 protein detected in #19 Tail FVB Tail E7/QuilAc 3/3 3/3
skin is immunogenic in FVB mice, skin homogenate from #19 E7/QuilAc 4/4 3/3
#19 and control mice was injected intrasplenically into Flank FVB Tail E7/QuilAd 1/1 1/1
Flank E7/QuilAe or f 14/14 8/8FVB recipients. Serum collected 50 days after a single
QuilAe or f 10/10 7/7injection of #19 homogenate demonstrated antibody to
Diseased flank Tail E7/QuilAd 2/2 2/2
HPV16E7 by immunoprecipitation (data not shown). Flank E7/QuilAe 3/3 1/1
QuilAe 3/3 2/2
Fate of E7 transgenic grafts on HPV16E7 immunized
a Recipient mice were immunized with 10 mg of GST–HPV16 E7recipients
fusion protein and 20 mg of QuilA, or 20 g of QuilA alone.
b No. of recipients with surviving grafts/No. of recipients.To determine whether immunization of recipients of c 31 and 9 days prior to grafting.
#19 skin grafts with HPV16E7 prior to grafting would alter d 45 and 37 days prior to grafting.
graft outcome, #19 tail skin or #19 diseased or normal e 6 days prior to grafting or on the day of grafting.
f 7–10 and 0 days prior to grafting.flank skin was grafted onto the tail or flank of #19 or FVB
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TABLE 4
Immune Responses to HPV16 E7 in E7-Immunized and Nonimmunized Recipients of Tail Skin Graftsa
DTH to E7 E7-specific CTL activity
(mm ear thickening 1 1002 { SEM)c,d (% Cr release)c,e
Recipient strain Immunizationb Day 16 post-imm Day 86 post-imm Day 10 post-imm Day 87 post-imm
FVB 1 C57BL/6J f E7/QuilA 17 { 3 16 { 2 52 { 7 68 { 4
FVB 1 C57BL/6J f QuilA 0 { 1 1 { 0 0 { 1 20 { 1
C57BL/6J g E7/QuilA 28 { 2 27 { 4 37 { 3 80 { 1
a Donor tail skin grafts were from F1(FVB 1 C57BL/6J) or F1(#19 1 C57BL/6J) hybrid mice, and donor strain was irrelevant to immune response.
b Mice were immunized with 10 mg of GST–HPV16 E7 fusion protein and 20 mg of QuilA, or 20 mg of QuilA alone at 10 and 0 days prior to
grafting.
c Results are from groups of 3 –6 mice.
d Ear thickness recorded average of difference between challenged ear and control ear.
e Percentage of lysis at an E:T ratio of 50:1 { 1 SEM.
f Tail skin graft recipients.
g Control group for immunization.
slightly thickened dermis with an increased presence of were nevertheless not rejected by E7-immunized F1 (FVB
1 C57BL/6J) hybrid recipients up to 80 days posttransfercollagen and a reduced fatty layer, but otherwise normal
morphology and no identifiable cellular infiltrate. E7/ (Table 5). Histological examination of grafts at 10 days
posttransfer showed a slightly thickened epidermis andQuilA-immunized recipients exhibited an antibody re-
sponse against three linear B epitopes of the E7 protein, dermis with a small predominantly mononuclear cellular
infiltrate variably dispersed between the graft bed andEYMLD, QAEPD, and an undefined B epitope present in
peptide GF109, and also against the peptide BT12D, muscle bundles, but no differences were observed be-
tween immunized or unimmunized recipients, or betweenwhich contains three linear E7 B epitopes.
recipients of F1 (#19 1 C57BL/6J) hybrid and F1 (FVB 1
C57BL/6J) hybrid grafts.Fate of E7 transgenic grafts on recipients with
induced cellular immunity to E7
Fate of E7 transgenic grafts on DNCB treated
recipientsAs no Tc epitope from the E7 protein has been defined
for the H-2q background, we were concerned that the lack Contact sensitizers such as DNCB have been used to
of rejection of E7/ve skin grafts by FVB mice reflected a recruit circulating T cells and to induce a DTH-type im-
lack of such an epitope on this genetic background. As mune response at the site of antigen challenge (Enk
a Tc epitope of E7 restricted by H-2Db has been defined, and Katz, 1992; Garrigue et al., 1994). Based on these
F1 (#19 1 C57BL/6J) hybrid or F1 (FVB 1 C57BL/6J) hy- observations and the lack of rejection of E7 expressing
brid mice were used as tail skin donors, and E7/QuilA skin grafts by E7-immunized mice, we applied DNCB
or Quil A-immunized F1 (FVB 1 C57BL/6J) hybrid mice as to grafts in an attempt to recruit immune effector cells,
graft recipients. Splenocytes from E7/Quil A-immunized including E7-specific effector precursors to the graft site.
graft recipients and from E7/QuilA-immunized C57BL/6J
mice had CTL precursors specific for E7 restricted
through H-2b, which recognize the Db-restricted nonamer TABLE 5
E7-derived peptide (RAHYNIVTF). There was no differ-
F1(#19 1 C57BL/6J) Tail Skin Grafts Are Retained by HPV16 E7-
ence in CTL response between recipients of F1 (FVB 1 Immunized or Non-E7-Immunized F1(FVB 1 C57BL/6J) Recipients
C57BL/6J) hybrid and F1 (#19 1 C57BL/6J) hybrid grafts.
Graft outcomebE7-specific killing of the E7 expressing H-2b cell line C2
was demonstrated in the range of 37–80% at an E:T
Donor strain Immunizationa Days 7–10 Days 80–100ratio of 50:1 in an 8-day in vitro recall assay (Table 4).
Immunized and grafted mice also demonstrated antibody #19 1 C57BL/6J E7/QuilA 3/3 2/2
to various E7 epitopes, and DTH to E7 protein, demon- Quil A 3/3 3/3
FVB 1 C57BL/6J E7/QuilA 3/3 3/3strated by ear challenge at 16 and 86 days postimmuni-
Quil A 3/3 3/3sation (Table 4). To control for any inflammatory effect of
the E7 challenge antigen, DTH was measured in E7- a Recipient mice were immunized with 10 mg of GST–HPV16 E7
challenged, non-E7-immunized mice and always resulted fusion protein and 20 mg of Quil A, or 20 mg of Quil A alone 7–10 and
in measurements of less than 5 1 1002 mm (Table 4). 0 days prior to grafting.
b No. of recipients with surviving grafts/No. of recipients.Tail skin grafts from F1 (#19 1 C57BL/6J) hybrid mice
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TABLE 6 DTH to E7, were unable to reject skin grafts expressing
viral E7 antigen.Persistence of HPV16 E7 Expressing (#19) Flank Skin Grafts on DNCB
Demonstration of E7 protein and/or mRNA in donorTreated, E7-Immunizeda FVB Recipients
skin suggests that failure to reject skin grafts was not a
DNCB dose Graft outcomeb consequence of inadequate transgene expression. Pre-
Donor liminary experiments using donor skin from FVB
Sensitize Challenge strain Days 7–10 Days 40–50
transgenic mice in which E7 is expressed from the K14
promoter (Herber et al., 1996) and in which there is 10-10 mg 2 mg #19 2/2 0/2
FVB 2/2 0/2 fold higher level of E7 expression in the skin have also
0.2 mg #19 2/2 2/2 resulted in nonrejection by E7-primed recipients. Further,
FVB 2/2 2/2 we have previously shown (Frazer et al., 1995) that a
humoral immune response is generated to E7 by #19a Recipient mice were immunized with 10 mg of GST–HPV16E7 fusion
mice after the onset of skin disease, confirming that suffi-protein and 20 mg of Quil A on 7–8 and 0 days prior to grafting.
b No. of recipients with surviving grafts/No. of recipients. cient antigen is expressed for induction of immunity, as
is also demonstrated here by the immune response ob-
served in naive mice immunized intrasplenically with E7
FVB mice were immunized twice with E7/Quil A or Quil transgenic skin.
A, and 7 or 8 days later were sensitized to DNCB and E7 is probably expressed in the KCs of #19 mouse
grafted with #19 and/or FVB flank skin. Eight days later skin as the phenotype associated with transgene expres-
recipients were challenged with DNCB at the graft site. sion is epithelial hyperplasia and cultured #19 KCs ex-
The most appropriate doses of DNCB to induce contact press E7 mRNA (data not shown). Previous studies,
sensitivity were determined from preliminary experi- which demonstrate lack of E7-specific tolerance at the
ments and from previously reported studies (Enk and whole animal level (Frazer et al., 1995), indicate that con-
Katz, 1992; Garrigue et al., 1994). E7/QuilA-immunized stitutive expression of E7 by professional APCs is un-
mice that received a sensitizing dose of 10 mg of DNCB likely. Rejection of grafts of allogeneic keratinocytes re-
and challenge dose of 0.2 mg retained both #19 and quire induction of an allospecific immune response by
FVB grafts until termination of the experiment at 40 days MHC class II expressing APCs within the graft (Rosen-
posttransfer (Table 6). Mice which received the same berg et al., 1989) or induction of primed allospecific ef-
sensitizing dose, but a 2-mg challenge dose lost all FVB fector cells by immunization. Prolonged survival of cul-
and #19 grafts by 12 days posttransfer. Skin at either tured KC allografts is observed in naive recipients (Ham-
side of the graft site was thickened but otherwise normal mond et al., 1987; Tinois et al., 1989; Kawai et al., 1993)
and within the graft site was an area of necrotic tissue. irrespective of an observed in vitro CTL alloreactive re-
When a sensitizing dose of 0.5 mg of DNCB and a chal- sponse (Cairns et al., 1994). Some viral proteins ex-
lenge dose of 50 mg was applied, or when vehicle alone pressed as a transgene in skin can initiate graft rejection,
was applied as a control, all E7/Quil A and Quil A-immu- including HIV-1 gp120 (Dumois et al., 1995), SV40 T-anti-
nized recipients retained #19 and FVB grafts until experi- gen (Wettstein et al., 1988b; Juretic and Knowles, 1989),
ment termination at 50 days posttransfer. Histologic ex- and Moloney murine leukemia virus (Wettstein et al.,
amination, 2 days post-DNCB challenge, of the site of 1988a). However, in contrast to our model, in each of
skin challenge of control nongrafted DNCB sensitized these other models the viral transgene is driven from a
and challenged mice showed some exudate on the skin constitutive promoter and is likely to be expressed in
surface and an intense dermal cellular infiltrate con- both KCs and APCs within the skin. Classic minor histo-
sisting of polymorphonuclear leucocytes, some mononu- compatibility antigens which initiate skin graft rejection
clear cells, and some small round cells, typical of a DTH (Graff and Snell 1969) are predominantly uncharacter-
reaction. At 42 days postchallenge, the graft site of all ized. The recently characterized H-Y antigen (Scott et al.,
recipients appeared histologically normal apart from a 1995) when expressed by KCs and professional APCs
slight thickening of the epidermis and dermis in those induces rejection of male skin grafts by naive female
treated with DNCB. recipients from Day 20 after graft transfer (Fuchs and
Matzinger, 1992). However, this antigen is immunogenic
only in certain mouse lines, not including the FVB line,DISCUSSION
as grafts from male #19 mice were not rejected by female
FVB mice.We have used #19 transgenic mice as a source of
skin expressing HPV16E7 to assess whether E7 could T help may also be necessary for effective skin graft
rejection mediated through a MTA. As with expressionfunction as a MTA and facilitate skin graft rejection. Our
studies have shown that unimmunized and E7-immu- of E7 in our study, expression of P91A, a tumor-specific
antigen, in isolation from other tumor antigens, failed tonized mice, in which an induced immune response to E7
was demonstrated by generation of E7 CTL precursors, stimulate a rejection response (Antoniou et al., 1996).
Rejection of skin grafts expressing P91A required coex-production of antibody to E7 peptides, and generation of
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pression of H-Y, and a recipient animal primed to both to be active in all cell types suggests that there is a
fundamentally different immunological outcome whenP91A and H-Y. This observation is similar to one in which
coexpression of H-Y is required to induce an SV40 T antigen is expressed only in KCs. Whether this apparent
tolerance of nonself is a non-antigen-specific conse-antigen-specific CTL response. However, the generation
of antibody and DTH to E7 in our experiments suggests quence of immunosuppressive cytokines secreted in
noninflamed skin, or represents specific tolerization ofthat E7-specific Th responses are induced through immu-
nization and leaves open the question as to why the cytotoxic immune effector cells exposed to cognate anti-
gen/MHC expressed on KCs with inappropriate costimu-grafts were not rejected, as a requirement for copresen-
tation is not observed in animals once priming is latory molecules, is currently under investigation.
achieved in the models described above, and an induced
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